Welcome to our dedicated page for Instil Bio SEC filings (Ticker: TIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Instil Bio, Inc. filings document formal disclosures for a biotechnology issuer whose recent business focus has included novel therapeutic opportunities and subsidiary-level clinical programs through Axion Bio. Current reports on Form 8-K furnish quarterly and annual financial results, corporate updates, capital resources, restructuring and impairment charges, and material events tied to clinical-development and license-collaboration matters.
Proxy materials describe annual stockholder meeting matters, director elections, board governance, and ratification of the independent registered public accounting firm. Other 8-K disclosures record the change in certifying accountant, including the appointment of RSM US LLP and the replacement of Deloitte & Touche LLP.
Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. reported beneficial ownership of 292,743 shares of Instil Bio, Inc. common stock, equal to 4.5% of the company based on 6,559,927 shares outstanding as disclosed May 9, 2025. The shares are held of record by Vivo Capital Fund IX, L.P., and Vivo Capital IX, LLC is the fund's general partner.
The Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, shows the reporting persons have sole voting and dispositive power over the 292,743 shares and includes a certification that the position was not acquired to change or influence control. The filing is signed by Frank Kung on 08/12/2025.